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Abstract
Background: The phase-space relationship between simultaneously measured myoplasmic [Ca2+]
and isovolumetric left ventricular pressure (LVP) in guinea pig intact hearts is altered by ischemic
and inotropic interventions. Our objective was to mathematically model this phase-space
relationship between [Ca2+] and LVP with a focus on the changes in cross-bridge kinetics and
myofilament Ca2+ sensitivity responsible for alterations in Ca2+-contraction coupling due to
inotropic drugs in the presence and absence of ischemia reperfusion (IR) injury.
Methods: We used a four state computational model to predict LVP using experimentally
measured, averaged myoplasmic [Ca2+] transients from unpaced, isolated guinea pig hearts as the
model input. Values of model parameters were estimated by minimizing the error between
experimentally measured LVP and model-predicted LVP.
Results: We found that IR injury resulted in reduced myofilament Ca2+ sensitivity, and decreased
cross-bridge association and dissociation rates. Dopamine (8 µM) reduced myofilament Ca2+
sensitivity before, but enhanced it after ischemia while improving cross-bridge kinetics before and
after IR injury. Dobutamine (4 µM) reduced myofilament Ca2+ sensitivity while improving cross-
bridge kinetics before and after ischemia. Digoxin (1 µM) increased myofilament Ca2+ sensitivity
and cross-bridge kinetics after but not before ischemia. Levosimendan (1 µM) enhanced
myofilament Ca2+ affinity and cross-bridge kinetics only after ischemia.
Conclusion: Estimated model parameters reveal mechanistic changes in Ca2+-contraction
coupling due to IR injury, specifically the inefficient utilization of Ca2+ for contractile function with
diastolic contracture (increase in resting diastolic LVP). The model parameters also reveal drug-
induced improvements in Ca2+-contraction coupling before and after IR injury.
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Introduction
We have described the utility of phase-space representa-
tions of simultaneously measured myoplasmic Ca2+ con-
centration ([Ca2+]) and left ventricular pressure (LVP) in
guinea pig intact hearts during spharmacologic and
pathophysiologic interventions [1-5]. We used several
novel indices to describe the morphological changes dis-
played in the LVP- [Ca2+] relationship that occur during
changes in the contractile state [3]. In the present study we
extended our phase-space analyses of LVP and [Ca2+] [5]
using mathematical modeling techniques to examine the
effects of ischemia reperfusion (IR) injury on changes elic-
ited by different positive inotropic agents. We used a the-
oretical four-state computational model (Figure 1, Table
1) [4,6-8] to explore mechanisms underlying formation of
LVP-Ca2+ loops, specifically the kinetic interactions
between actin and myosin cross-bridges, and between
Ca2+ and troponin C with pharmacologic interventions. In
a previous study we demonstrated that this four-state
model is capable of reproducing the dominant character-
istics of the mechanisms underlying Ca2+-contraction cou-
pling during hypothermic perfusion and after
normothermic short-term and hypothermic long-term IR
injury [4].
Our objective was to determine how positive inotropic
drugs with differing pharmacological mechanisms of
action affect estimated rates of cross-bridge cycling and
myofilament Ca2+ handling before and after IR injury
from the phase-space relationship of Ca2+-contraction
coupling. The model parameters were estimated using
data obtained from guinea pig spontaneously beating,
isolated hearts at physiologic temperature)[5]. Three
pharmacological classes of positive inotropes were exam-
ined: dopaminergic and adrenergic agonists (i.e.,
dopamine, dobutamine), a Na+/K+ ATPase inhibitor (i.e.,
digoxin), and a so-called myofilament Ca2+ sensitizer with
phosphodiesterase inhibiting properties (i.e., levosi-
mendan). While each of these drugs increases myoplas-
mic [Ca2+] ("upstream" mechanism), their effects on Ca2+
binding to troponin C ("central" mechanism) and actino-
myosin cross-bridge cycling ("downstream" mechanism)
remain unexplored or controversial.
Several investigators have reported an increase in cross-
bridge formation by post-synaptic adrenoceptor agonists
[9,10], but others have failed to confirm these findings
[11]. Digoxin may regulate formation of cross-bridges
[12] but its effect on Ca2+ affinity for troponin C is
unclear. However, another Na+/K+ ATPase inhibitor, oua-
bain, was shown to increase cross-bridge kinetics and
myofilament Ca2+ cycling in ventricular myocardium
from patients with heart failure [13]. Ca2+ sensitizers are
believed to improve myofilament Ca2+ sensitivity by
enhancing troponin C sensitivity for Ca2+ and may also
alter cross-bridge attachment and detachment rate con-
stants [14]. One of these, levosimendan, is reported to
bind to troponin C in the presence of Ca2+ and to stabilize
the Ca2+- troponin C complex without increasing Ca2+
binding affinity with troponin C [15]. In guinea pig pap-
illary muscles paced at room temperature, levosimendan
prolonged the attachment of cross-bridges [16], acceler-
ated cross-bridge association and decelerated cross-bridge
dissociation rate constants [17]. It is unknown if IR injury
alters these effects of levosimendan on contraction kinet-
ics. Our model provides additional insight into myofibril-
lar protein interactions responsible for translating phasic
changes in [Ca2+] into myocardial contraction and relaxa-
tion before and after IR injury in the presence and absence
of these inotropic drugs.
Methods
The investigation conformed to the Guide for the Care and
Use of Laboratory Animals from the US National Institutes
of Health (NIH No. 85–23, Revised 1996). Prior approval
was obtained from the Medical College of Wisconsin and
Marquette University Animal Studies Committees.
Guinea pig heart isolation and our fluorescence technique
to measure myoplasmic free [Ca2+] has been detailed in
previously published work [1-5,18-24], and are only
briefly described here. Albino English short-haired guinea
Block diagram of a biochemical model relating the input/out-put relationship between yoplasmic [Ca2+] and LVP adapte  from Bar n et alFigure 1
Block diagram of a biochemical model relating the input/out-
put relationship between myoplasmic [Ca2+] and LVP 
adapted from Baran et al.[7] and Shimizu et al.[8] The 4-state 
model is governed by 5 differential equations. TnCA repre-
sents the troponin C molecule on the actin (A) myofilament, 
M represents the myosin head, + indicates weak bonds and • 
represents strong bonds. The sequence of events from pha-
sic [Ca2+] to contraction are as follows: Ca2+ binds to TnCA, 
tropomyosin shifts so M and A can bind forming an actinomy-
osin cross-bridge, Ca2+ dissociates from TnCA with cross-
bridge attached, and finally the cross-bridge breaks. Model 
rate constants and their units are indicated by their sites of 
action and described in Table 1. Note that A and M cannot 
form cross-bridges in the absence of Ca2+; however, since 
this is a loose coupling model, once a cross-bridge has been 
formed it no longer requires associated Ca2+ to remain 
attached.
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pigs (n = 40) were anesthetized with 30 mg ketamine i.p.
and treated with heparin (1000 units). The animals were
then decapitated when unresponsive to noxious stimula-
tion. After thoracotomy the inferior and superior venae
cavae were cut away and the aorta was cannulated distal to
the aortic valve. Each heart was immediately perfused via
the aortic root with a cold oxygenated, modified Krebs-
Ringer's (KR) solution (equilibrated with 97% O2 and 3%
CO2) at an aortic root perfusion pressure of 55 mmHg
and was then rapidly excised. The KR perfusate (pH 7.39
± 0.01, pO2 620 ± 10 mmHg) was filtered (5 µm pore size)
in-line and has the following calculated composition in
mM (non-ionized): Na+ 137, K+ 5, Mg2+ 1.2, Ca2+ 1.25, Cl-
134, HCO3 - 15.5, H2PO4 - 1.2, glucose 11.5, pyruvate 2,
mannitol 16, EDTA 0.05, probenecid 0.1, and insulin 5
(U/L). Perfusate and bath temperatures were maintained
at 37.2 ± 0.1°C using a thermostatically controlled water
circulator. KR with reduced [CaCl2] (1.25 mM) allowed a
wider range of inotropic responses at a lower control LVP.
LVP was measured isovolumetrically with a transducer
connected to a thin, saline-filled latex balloon inserted
into the LV through the mitral valve from an incision in
the left atrium. Balloon volume was adjusted initially to a
diastolic LVP of zero mmHg so that any subsequent
increase in diastolic LVP reflected an increase in LV wall
stiffness i.e., diastolic contracture. Pairs of bipolar elec-
trodes were placed in the right atrial appendage, right ven-
tricular apex and LV base to monitor spontaneous heart
rate and atrial-ventricular conduction time. Coronary
flow (aortic inflow, CF) was measured at constant temper-
ature and perfusion pressure (55 mmHg) by an ultrasonic
flowmeter (Transonic T106X, Ithaca, NY) placed directly
into the aortic inflow line.
The Ca2+ indicator indo-1 AM (Sigma Chemical, St. Louis,
MO) was dissolved in vehicle solution consisting of 1 mL
of dimethyl sulfoxide (DMSO) containing 16 % (w/v)
Pluronic I-127 (Sigma Chemical) and diluted to 165 mL
with modified KR solution. Each heart was then loaded
with indo-1 AM for 30 min with the re-circulated KR solu-
tion, which had a final indo-1 AM concentration of 6 µM.
Loading was stopped when the fluorescence (F) intensity
at 385 nm increased by about 10 fold. Residual interstitial
indo-1 AM was washed out by perfusing the heart with KR
for another 20 min. Probenecid (100 µM) was present in
the perfusate to retard cell leakage of indo-1. Fluorescence
emissions at 385 and 456 nm (F385 and F456) were
recorded using a modified luminescence spectrophotom-
eter (SLM Aminco-Bowman II, Spectronic Instruments,
Urbana IL). The LV region of the heart was excited with
light from a xenon arc lamp and the light was filtered
through a 360 nm monochromator with a bandwidth of
16 nm. Although both F385 and F456 decline over time,
time control studies showed that the F385/F456 ratio
remained stable indicating that the effective measured
[Ca2+] was unchanged [19]. The total exposure time to the
350 nm excitation wavelength light was 62.5 s. Custom-
ized software was developed in MATLAB® for off-line sig-
nal processing of the recorded data. The F385/F456 ratio was
converted to [Ca2+] after correcting for background
autofluorescence and non-cytosolic fluorescence as
described in our previously published work. [1-5,18-24].
Experimental protocol and data collection
Unpaced hearts were randomly assigned to receive dob-
utamine (4 µM), dopamine (8 µM), digoxin (1 µM), or
levosimendan (1 µM) (n = 8 in each group). Each ino-
tropic drug was infused for 2 min 30 min before global
ischemia. Next, hearts were subjected to a 30 min period
of global ischemia and inotropic drugs were again infused
for 2 min after 30 min reperfusion. The concentrations of
inotropic drugs were the approximate ED50 concentra-
tions as previously established [2,3]. Eight control hearts
were not exposed to inotropic interventions before or
after global ischemia. At the end of each experiment
MnCl2 (100 µM) was infused for 10 min to quench the
myoplasmic indo-1 Ca2+ signal to correct for the non-
myoplasmic fraction. All analog signals were digitized and
recorded at 125 Hz for later analysis using MATLAB® as
previously described [3].
Simultaneous recordings of [Ca2+] and LVP were obtained
at selected intervals before and during administration of
Table 1: Model parameters and brief description.
Parameter Name Description
K1 (1/µM•s) Cooperative binding rate constant of Ca2+ to TnCA
Ka (1/µM•s) Cooperative rate constant of formation of A•M
K2 (1/µM•s) Association rate constant of Ca2+ to A•M
K3 (1/s) Dissociation rate constant of Ca2+ from TnCA
K4 (1/s) Dissociation rate constant of Ca2+ from A•M
Kd (1/s) Dissociation rate constant of A•M in the presence of attached Ca2+
Kd' (1/s) Dissociation rate constant of A•M in the absence of attached Ca2+
K = rate constants characterizing the 4-state model are pictured in Figure 1 and described in detail in the Appendix. A = Actin, M = Myosin, TnCA 
= Troponin C on the A filament, A•M = actinomyosin cross-bridges.
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Sample time series plots of LVP and [Ca2+] from Control (A), Dobutamine (B), Dopamine (C), Digoxin (D), and Levosimendan (E) before (left panel) and after (right p nel) ischemia [5]Figur  2
Sample time series plots of LVP and [Ca2+] from Control (A), Dobutamine (B), Dopamine (C), Digoxin (D), and Levosimendan 
(E) before (left panel) and after (right panel) ischemia [5]. Diastolic Ca2+ detection points are shown for control. Extracellular 
CaCl2 was half-normal (1.2 mM) to allow for a full range of responses to the drugs. This accounts for the lower control values 
of systolic LVP and [Ca2+]. Phasic LVP was lower after ischemia in all groups but phasic [Ca2+] was higher only in the control 
group (see table 1).
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inotropic drugs and IR (Figure 2A–E). The timing of peak
diastolic [Ca2+] for each cardiac cycle was obtained over
the 2.5 s recordings using a simple event detection algo-
rithm. The [Ca2+], and simultaneously obtained LVP sig-
nals between each consecutively detected Ca2+ diastolic
point, were aligned and averaged on a point by point basis
to form the averaged [Ca2+] and LVP transient signals. Any
dysrhythmic beats were excluded from the averaged [Ca2+]
and LVP transient signals. LVP was plotted as a function of
myoplasmic [Ca2+] over a representative cardiac cycle to
create phase-space diagrams. These diagrams represent the
dynamic relationship between trigger Ca2+ and the result-
ing pressure development due to central and downstream
mechanisms. Because we are unable to directly measure
the interactions between Ca2+ and troponin C, or the
kinetics of cross-bridge cycling, we utilized a previously
developed a mathematical model to help elucidate effects
of changes in myofilament interaction that contribute to
changing the dynamic relationship between LVP and
Ca2+.
Description and assumptions of mathematical model
The mathematical model utilized for the interpretation of
our kinetic data allows for the interaction between tro-
ponin C attached to the actin (A) myofilament (TnCA)
and myosin (M) for cross-bridge formation and force
development in the presence of Ca2+ [4,6-8,25]. The
model (Figure 1, Table 1) consists of four stages governed
by the following five differential equations:
LVP, as predicted by the model (LVPMod), is proportional
to the number of cross-bridges formed: [Ca•TnCA•M] +
[TnCA•M] [7]. Cooperativity, the positive feedback mech-
anism responsible for a rise in force, has been attributed
to effects of cross-bridge formation on neighboring cross-
bridges and/or effects of Ca2+ binding to TnCA on neigh-
boring tropomyosin units [26,27]. In accordance with
Baran et al. [7] and Shimizu et al. [8], we accounted for
cooperative contraction and relaxation by allowing K1 and
Ka to vary according to functions described as:
The α parameter represents the slopes of the K1 and Ka
curves and is a measure of sensitivity of the cooperative
mechanism; an increase in α represents accelerating inter-
actions between TnCA and Ca2+ (α1) and actinomyosin
cross-bridges (αa). The β parameter represents the static
value of K1 and Ka at 0 LVP; an increase in β indicates an
increase in the resting value of the affinity of TnCA and
Ca2+ (β1) and cross-bridge attachment (βa).
We assumed a "loose coupling" model where Ca2+ disso-
ciates from TnCA before the M head detaches from the A
molecule [28]. We also assumed that the transition
between weak and strong cross-bridge conformations is
rapid and not rate-limiting [29]. Finally, we assumed that
changes in sarcomere length had little effect on the rela-
tionship between myoplasmic Ca2+ and isovolumic LVP.
Kentish and Wrzosek [30] reported that lengthening of rat
isolated myocardium increased twitch force but had no
effect on the magnitude of the Ca2+ transient, suggesting
an increase in myofilament Ca2+ sensitivity. In contrast,
Shimizu et al. [8] reported no length-dependent altera-
tions in myofilament Ca2+ binding or cross-bridge cycling
in canine isolated, blood-perfused hearts.
Kinetic analysis
The experimentally measured and averaged Ca2+ tran-
sients were lowpass filtered at 25 Hz and upsampled to
2500 Hz using a linear interpolation scheme prior to their
use as model forcing functions. The governing differential
equations were solved numerically using a 4th order
Runge-Kutta algorithm (on a MATLAB® platform) with a
0.4 ms step size equal to the post-interpolation sampling
interval and the following initial conditions [7,8,25,26]:
[TnCA](t = 0) = 70 µM, [M](t = 0) = 20 µM, [Ca•TnCA](t = 0) =
0 µM, [Ca•TnCA•M](t = 0) = 0 µM, and [TnCA•M](t = 0) = 0µM.
Model rate constants were optimized using commercially
available algorithms based on constrained quasi-Newton
methods that guarantee linear convergence, and were esti-
mated to minimize the root mean square (RMS) error
between LVPMod and LVP at the sampled time points.
Lower and upper bounds for optimization of 1st order rate
constants were set at 0 and 2000 /sec (0.5 ms step size)
respectively. Initial values for the parameters were
obtained from Baran et al. [7]. Several constraints were
imposed on the model rate constants during optimiza-
tion. To ensure a positive feedback, α1 and αa must be
greater than 0. Kd' must be greater than Kd since cross-
bridges dissociate more readily in the absence of attached
Ca2+; Kd' accounts for the physiological difference
d TnCA
dt
K Ca TnCA K Ca TnCA K TnCA M
d M
dt
K
d
d
[ ]
[ ][ ] [ ] [ ]
[ ]
[
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between contraction and relaxation kinetics [7]. The max-
imum rate constant of Ca2+ binding to TnCA with
attached cross-bridges must be greater than the maximum
rate constant of Ca2+ binding to TnCA with no attached
cross-bridges (K2>K1); this concept incorporates the idea
of a positive feedback mechanism to explain the delay in
rise in LVP during contraction [31].
Statistical analysis
Model rate constants computed before and during admin-
istration of inotropic drugs and IR were compared using
one-way ANOVA followed by Dunnett's comparison of
means post-hoc test (MINITAB™ Statistical Software
Release 13.3, Minitab Inc, State College, PA). Post-
ischemic values of control and inotropic drugs were com-
pared to their respective pre-ischemic values using Stu-
dent's paired t-test. Differences among means were
considered statistically significant at P < 0.05 (two-tailed).
All experimental measurements and model rate constants
were expressed as means ± SE.
Results
The effects of drugs and ischemia on heart rate and phasic
LVP and [Ca2+] have been previously reported [5] and are
presented again in table 2. Note that IR injury had no
effect on heart rate either in the presence or absence of
drugs. Conversely, dobutamine and dopamine both
increased heart rate from control before and after
ischemia. Digoxin did not change heart rate before or after
ischemia and levosimendan increased heart rate before,
but not after ischemia.
Experimentally measured LVP, plotted as a function of
[Ca2+], is represented by symbols for all interventions
before (A) and after (B) ischemia in figure 3. Correspond-
ing LVPMod, plotted as a function of [Ca2+], is represented
by the dashed line for all interventions. Typical plots of
the estimated cooperative parameters K1 (A) and Ka (B) as
a function of the total number of cross-bridges formed
([Ca•TnCA•M]+[TnCA•M]) for all groups before and
after ischemia are shown in figure 4. Estimated model
parameters before and after global ischemia is reported in
table 3 and the effects of drugs and ischemia or model
parameters are summarized in tables 4 and 5.
Effects of ischemia alone
The model described Ca2+-contraction coupling with rela-
tively small errors between LVPMod and LVP before (3.2 ±
0.5%) and after (2.2 ± 0.3%) IR injury. The model pre-
dicted:
a) Decreased cooperativity of Ca2+ affinity for TnCA and
cross-bridge association as demonstrated by the marked
decreases in slopes of K1 and Ka respectively, after
ischemia.
b) Decreased cross-bridge dissociation rate constants Kd,
and Kd' after ischemia.
c) Decreased K2 but increased K4 after ischemia; this indi-
cates impaired myofilament Ca2+ sensitivity when cross-
bridges are attached.
Effects of dopamine
The model described Ca2+-contraction coupling during
dopamine administration with errors of 3.5 ± 0.7% and
2.6 ± 0.4% before and after ischemia, respectively. The
model predicted:
Table 2: Effects of inotropic drugs before and after global ischemia on morphological and temporal indices [5]
Before Ischemia After Ischemia
Con Dbt Dop Dig Lev Con Dbt Dop Dig Lev
Heart Rate (beats per minute)
236 ± 3 350 ± 12* 298 ± 9* 259 ± 6 270 ± 5* 242 ± 8 350 ± 15# 298 ± 13# 269 ± 10 271 ± 7
Systolic LVP (mmHg)
32 ± 1 73 ± 5* 55 ± 3* 49 ± 2* 51 ± 2* 29 ± 2 44 ± 3#† 40 ± 1#† 37 ± 2#† 35 ± 2#†
Diastolic LVP (mmHg)
3 ± 1 2 ± 1 4 ± 1 6 ± 1 3 ± 2 13 ± 2† 13 ± 2† 13 ± 2† 14 ± 1† 18 ± 2†
Phasic (systolic-diastolic) LVP (mmHg)
28 ± 2 71 ± 6* 52 ± 3* 43 ± 1* 48 ± 3* 16 ± 2† 32 ± 4#† 27 ± 2#† 23 ± 2#† 17 ± 3†
Systolic [Ca2+] (nM)
258 ± 4 609 ± 48* 307 ± 14* 301 ± 10* 367 ± 31* 381 ± 27† 544 ± 56# 310 ± 19# 333 ± 22 369 ± 24
Diastolic [Ca2+] (nM)
103 ± 2 140 ± 10* 108 ± 4 106 ± 2 110 ± 3 124 ± 9† 148 ± 13 107 ± 9 100 ± 6# 124 ± 10
Phasic (systolic-diastolic) [Ca2+] (nM)
155 ± 5 469 ± 72* 198 ± 12* 194 ± 10* 257 ± 32* 257 ± 19† 396 ± 53# 204 ± 20 234 ± 17 245 ± 23
Values are expressed as mean ± SE. [CaCl2] was 1.25 mM. Con = Control, Dbt = Dobutamine, Dop = Dopamine, Dig = Digoxin, Lev = 
Levosimendan. Statistical significance was measured at *p < 0.05 vs. Control before ischemia, #p < 0.05 vs. Control after ischemia, †p < 0.05 after 
vs. before ischemia for all groups.
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Typical plots of LVP and LVPMod vs [Ca2+] averaged over all beats in the 2.5 second recordings for all groups before (A) and after (B) ischemiaFigure 3
Typical plots of LVP and LVPMod vs [Ca2+] averaged over all beats in the 2.5 second recordings for all groups before (A) and 
after (B) ischemia. Experimental data are represented by markers and the model fit is represented by dotted lines.
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Model-predicted cooperative rate constants K1 (A) and Ka (B) vs.the total number of formed cross-bridges, [Ca•TnCA•M] + [TnCA•M] for all experimental groups before (left after (right) ischemiaFigure 4
Model-predicted cooperative rate constants K1 (A) and Ka (B) vs. the total number of formed cross-bridges, [Ca•TnCA•M] + 
[TnCA•M] for all experimental groups before (left) and after (right) ischemia. Ischemia alone resulted in a decrease in the max-
imum estimated number of formed cross-bridges from 14.2 µM to 9.2 µM. The maximal estimated number of formed cross-
bridges with dopamine and dobutamine were less than control before ischemia (7.3 µM and 11.8 µM, respectively) and greater 
than control after (10.6 µM and 12.7 µM, respectively) ischemia. After ischemia digoxin increased the maximum estimated 
number of formed cross-bridges (13.6 µM) compared to control.
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a) Reduced interactions between Ca2+ and TnCA before
ischemia by dopamine as noted by the reduced values of
α1 and K3, and by the increased value of K4 compared to
control.
b) Increased interaction between Ca2+ and TnCA after
ischemia by dopamine as noted from the increased values
of α1 and K3 compared to control.
c) Increased values of αa, Kd, and Kd' before ischemia by
dopamine; this indicates improved cross-bridge cycling
compared to control.
d) Improved cross-bridge kinetics compared to control
after ischemia by dopamine as shown by increased esti-
mates of αa, βa, and Kd; however, this improvement was
significantly less than the improvement noted with
dopamine before ischemia.
Effects of dobutamine
The model successfully described the relationship
between [Ca2+] and LVP during dobutamine administra-
tion with low errors of 5.0 ± 0.5% before and 3.0 ± 0.4%
after ischemia. The model predicted:
a) Reduced sensitivity of Ca2+ binding to TnCA in dob-
utamine-treated hearts compared to control before
ischemia as shown by the decrease in α1; however, Ca2+
association and dissociation with actinomyosin cross-
bridges, K2 and K4 respectively, was increased.
b) Marked increases in cross-bridge kinetics, i.e., αa, Kd,
and Kd' before ischemia by dobutamine compared to con-
trol.
c) Reduced affinity of Ca2+ for TnCA as assessed from
decreased βa and increased K4 after ischemia by dob-
utamine compared to control.
d) Improved cross-bridge kinetics from increased αa, βa,
and Kd after ischemia by dobutamine compared to con-
trol.
e) Reduced cooperative myofilament Ca2+ affinity (α1)
and cross-bridge association (αa), increased basal rate
constant of Ca2+ binding to TnCA (β1), and reduced basal
rate constant of cross-bridge association (βa) by dob-
utamine treatment after ischemia as compared to dob-
utamine treatment before ischemia. These predictions
resulted in plots of K1 and Ka (figure. 3) being flatter dur-
ing administration of dobutamine after than before
ischemia.
f) Reduced non-cooperative affinity of Ca2+ for the formed
cross-bridge, K2, and reduced cross-bridge dissociation
rates Kd and Kd' by dobutamine treatment before ischemia
as compared to dobutamine treatment after ischemia.
Table 3: Effects of positive inotropic drugs on model parameters when administered before and after global ischemia.
Before Ischemia After Ischemia
Con Dbt Dop Dig Lev Con Dbt Dop Dig Lev
Second order rate constants Second order rate constants
α1 (1/µM•s) α1 (1/µM•s)
4.5 ± 0.3 2.2 ± 0.2* 2.3 ± 0.3* 4.2 ± 0.3 4.4 ± 0.5 0.5 ± 0.1† 0.5 ± 0.2† 1.2 ± 0.2# 1.1 ± 0.2#† 1.6 ± 0.4#†
αa (1/µM•s) αa (1/µM•s)
5.0 ± 0.2 8.0 ± 0.8* 14 ± 3* 5.8 ± 0.5 5.2 ± 0.3 1.7 ± 0.4† 4 ± 1#† 3.8 ± 0.6#† 4.2 ± 0.7# 2.4 ± 0.4†
β1 (1/µM•s) β1(1/µM•s)
0.12 ± 0.07 0.18 ± 0.15 2.2 ± 0.8* 0.2 ± 0.1 1.8 ± 0.9 10 ± 3† 4 ± 1#† 9.0 ± 0.5† 10 ± 2† 5.7 ± 2.0#†
βa (1/µM•s) βa (1/µM•s)
118 ± 12 83 ± 9 29 ± 13* 110 ± 10 56 ± 9* 5.2 ± 0.7† 10 ± 2#† 11 ± 3#† 13 ± 4#† 15 ± 8#†
K2 (1/µM•s) K2(1/µM•s)
418 ± 14 775 ± 82* 355 ± 68 485 ± 59 351 ± 62 151 ± 63† 275 ± 41† 262 ± 76 249 ± 28† 250 ± 9#†
First order rate constants First order rate constants
K3 (1/s) K3 (1/s)
429 ± 24 348 ± 46 174 ± 42* 434 ± 31 508 ± 63 271 ± 39† 270 ± 43 517 ± 26#† 480 ± 24# 178 ± 19#†
K4 (1/s) K4 (1/s)
18 ± 4 80 ± 17* 52 ± 9* 28 ± 9 37 ± 7* 60 ± 8† 90 ± 10# 65 ± 11 69 ± 6† 67 ± 13†
Kd (1/s) Kd (1/s)
484 ± 21 872 ± 29* 656 ± 54* 500 ± 20 593 ± 71 87 ± 13† 331 ± 27#† 183 ± 30#† 227 ± 77#† 325 ± 47#†
Kd'(1/s) Kd'(1/s)
765 ± 81 977 ± 32* 1218 ± 11* 728 ± 88 751 ± 64 377 ± 25† 375 ± 15† 378 ± 1† 450 ± 72† 398 ± 27†
Values are expressed as mean ± SE. Con = Control, Dbt = Dobutamine, Dop = Dopamine, Dig = Digoxin, Lev = Levosimendan. Statistical 
significance was measured at *p < 0.05 vs. Control before ischemia, #p < 0.05 vs. Control after ischemia, †p < 0.05 after vs. before ischemia in the 
presence or absence of drugs.
BioMedical Engineering OnLine 2006, 5:16 http://www.biomedical-engineering-online.com/content/5/1/16
Page 10 of 14
(page number not for citation purposes)
Effects of digoxin
The model described Ca2+-contraction coupling during
digoxin administration with 5.0 ± 0.6% and 2.0 ± 0.3%
errors before and after ischemia, respectively. The model
predicted:
a) No effects on myofilament Ca2+ sensitivity or cross-
bridge kinetics before ischemia by digoxin compared to
control.
b) Increased sensitivity of Ca2+ affinity for TnCA, α1, and
dissociation of Ca2+ from TnCA, K3, after ischemia by dig-
oxin compared to control.
c) Improved cross-bridge cycling as noted from the
increased values of αa, βa, and Kd after ischemia by digoxin
compared to control.
d) Reduced cooperative and non-cooperative affinities of
Ca2+ for TnCA, α1 and K2 respectively, by digoxin treat-
ment after ischemia as compared to digoxin treatment
before ischemia.
e) Enhanced Ca2+ dissociation from cross-bridges, K4, by
digoxin treatment after ischemia as compared to digoxin
treatment before ischemia.
f) Reduced cross-bridge dissociations, Kd, and Kd', by dig-
oxin treatment after ischemia compared to digoxin treat-
ment before ischemia.
Effects of levosimendan
The model described Ca2+-contraction coupling during
administration of levosimendan with 4.0 ± 0.3% and 1.7
± 0.3% errors before and after ischemia, respectively. The
model predicted:
a) Depressed cross-bridge association with a decrease in
βa, and enhanced myofilament Ca2+ dissociation with an
increase in K4 before ischemia by levosimendan compared
to control; however, none of the other parameters were
significantly changed by levosimendan compared to con-
trol before ischemia.
b) Increased sensitivity of Ca2+ affinity for TnCA as noted
from increased values of α1 and K2, and the decreased
value of K3 after ischemia by levosimendan compared to
control.
c) Enhanced basal rate constant of cross-bridge associa-
tion, βa, and dissociation, Kd, after ischemia by levosi-
mendan compared to control.
d) Ischemia blunted the effects of levosimendan on all
model parameters except the basal rate constant of Ca2+
binding to TnCA, β1, and Ca2+ dissociation from actino-
myosin cross-bridges, K4.
Discussion
The results indicate: 1) the four-state model with cooper-
ativity is capable of interpreting changes in central and
downstream regulation of contractility due to inotropic
drugs in the presence and absence of IR injury in guinea
pig isolated hearts from the phase-space relationship
between [Ca2+] and LVP; 2) IR injury in the absence of
inotropic agents resulted in reduced Ca2+ affinity for
TnCA, and decreased cross-bridge kinetics; 3) dopamine
enhanced cross-bridge kinetics before and after ischemia;
4) dopamine decreased myofilament Ca2+ affinity before
ischemia but enhanced this affinity after ischemia; 5) in
contrast, dobutamine reduced myofilament Ca2+ sensitiv-
ity, and increased cross-bridge kinetics before and after
ischemia; and 6) digoxin and levosimendan improved
Table 4: Summary of drug-induced differences in model parameters compared to control.
Before Ischemia After Ischemia
Parameter Dbt Dop Dig Lev Dbt Dop Dig Lev
α1 (1/µM•s) ↓ ↓ NC NC NC ↑ ↑ ↑αa (1/µM•s) ↑ ↑ NC NC ↑ ↑ ↑ NCβ1 (1/µM•s) NC ↑ NC NC ↓ NC NC ↓βa (1/µM•s) NC ↓ NC ↓ ↑ ↑ ↑ ↑
K2 (1/µM•s) ↑ NC NC NC NC NC NC ↑
K3 (1/s) NC ↓ NC NC NC ↑ ↑ ↓
K4 (1/s) ↑ ↑ NC ↑ ↑ NC NC NC
Kd (1/s) ↑ ↑ NC NC ↑ ↑ ↑ ↑
Kd' (1/s) ↑ ↑ NC NC NC NC NC NC
Arrows indicate directional differences in drug effects on model parameters from pre- and post-ischemic controls. NC = no change. Data obtained 
25 min before and 35 min after global ischemia in the presence of drugs.
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Ca2+ affinity for TnCA and cross-bridge association after
ischemia but neither drug substantially affected these
parameters before ischemia.
IR injury and Ca2+-contraction coupling
Theoretical models of Ca2+-contraction coupling during
pharmacological and pathophysiological interventions
have not been extensively examined. Winslow et al. [32]
presented a computational model of excitation-contrac-
tion coupling during congestive heart failure in the guinea
pig ventricular cell and demonstrated that simultaneous
up-regulation of Na/Ca exchange and down-regulation of
SR Ca-ATPase pump activity may account for the reduced
amplitude of Ca2+ transients in failing ventricular myo-
cytes. Ch'en et al. [33] modeled cardiac metabolism dur-
ing normal and ischemic conditions with particular
attention to reperfusion arrhythmias resulting from
sodium and calcium overload. However, neither of these
models examined the effects of IR injury on Ca2+-medi-
ated kinetic interactions between contractile and regula-
tory proteins.
Previously, we applied this same four-state model to study
central and downstream mechanisms regulating Ca2+-
contraction coupling in long-term cold IR injury com-
pared to short-term warm IR injury [4]. Based on the
model parameters, we predicted a marked decrease in
actinomyosin cross-bridge cycling and reduced myofila-
ment Ca2+ sensitivity during hypothermic perfusion. The
model also predicted better preservation of cooperativity
in cross-bridge cycling and myofilament Ca2+ handling
after long term cold IR injury compared to short term
warm IR injury despite cold-induced myoplasmic Ca2+
loading.
The present investigation used dynamic changes in Ca2+-
contraction coupling from experimentally derived phase-
space diagrams of LVP vs. [Ca2+] that have been analyzed
qualitatively [5], to examine changes in cross-bridge
kinetics and myofilament Ca2+ binding associated with IR
injury. The model's results suggest that IR injury causes
inefficient utilization of available [Ca2+] for contractile
function. The model-estimated parameters revealed that
IR injury results in reduced myofilament sensitivity for
Ca2+ binding; however, the basal rate constant of Ca2+
binding to TnCA was increased. This may reflect excess
myoplasmic Ca2+ loading despite concomitant reduction
of myofilament Ca2+ sensitivity. IR injury also resulted in
attenuation of model-predicted cross-bridge kinetics and
formation of fewer cross-bridges. Decreased ATP produc-
tion and hydrolysis may account for the reduction in
cross-bridge dissociation rate constants, Kd and Kd'. These
alterations in intracellular Ca2+ homeostasis may have
precipitated the rise in diastolic LVP and the reduction in
LV compliance as noted from the phase-space diagram
after ischemia in isolated hearts.
Dopaminergic and β-adrenergic agonists and Ca2+-
contraction coupling
Stimulation of dopaminergic and β1-adrenergic receptors
by dopamine and dobutamine has been shown to
increase myoplasmic cyclic adenosine 3', 5'-monophos-
phate (cAMP) levels and to activate cAMP-dependent pro-
tein kinase A. This protein kinase phosphorylates
sarcolemmal Ca2+ channels, SR Ca-ATPase, and troponin
I on actin myofilaments [34,35]. However, it is unclear
whether protein kinase-mediated phosphorylation of var-
ious proteins involved in contractile activation alters
cross-bridge dynamics [9-11]. Results from the present
model support our previous findings that dopamine
reduces myofilament sensitivity to Ca2+ before ischemia,
but enhances it after IR injury [2,3,5]. Large increases in
estimated rate constants of cross-bridge kinetics were also
observed that may be attributed partially to the positive
chronotropic effects of dopamine. Similarly, an increase
in heart rate produced by dopamine may also contribute
to the estimation of fewer formed cross-bridges before
ischemia as observed in figure 4. After ischemia,
dopamine resulted in a greater number of attached cross-
bridges despite increased heart rate; this is likely associ-
Table 5: Summary of differences in model parameters for each group after ischemia
Parameter Con Dbt Dop Dig Lev
α1 (1/µM•s) ↓ ↓ ↓ ↓ ↓αa (1/µM•s) ↓ ↓ ↓ NC ↓β1 (1/µM•s) ↑ ↑ ↑ ↑ ↑βa (1/µM•s) ↓ ↓ ↓ ↓ ↓
K2(1/µM•s) ↓ ↓ NC ↓ ↓
K3 (1/s) ↓ NC ↑ NC ↓
K4 (1/s) ↑ NC NC ↑ ↑
Kd (1/s) ↓ ↓ ↓ ↓ ↓
Kd' (1/s) ↓ ↓ ↓ ↓ ↓
Arrows indicate directional differences in model parameters after ischemia compared to before ischemia in each group. NC = no change. Data 
obtained 25 min before and 35 min after global ischemia in control hearts (no drug treatment).
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ated with slower estimated cross-bridge dissociation rate
constants (Kd and Kd'). Model parameters also suggested
that dobutamine, like dopamine, decreased myofilament
sensitivity to Ca2+ before ischemia. In contrast to the find-
ings with dopamine, myofilament Ca2+ sensitivity was
unchanged by dobutamine after ischemia. These differen-
tial effects of dopamine and dobutamine on myofilament
Ca2+ sensitivity after ischemia can also be observed from
differences in phase-space morphology exhibited by the
two drugs [5]. Cross-bridge kinetics were significantly
increased by dobutamine before and after ischemia, and
this was possibly related to an increase in heart rate. Our
results show that whereas heart rates were increased
approximately 50% by dobutamine prior to ischemia, the
1st order rate constants (K3, Kd and Kd') increased by
400%, 80%, and 27% respectively. This discrepancy may
be attributed to dobutamine-induced changes in myofila-
ment Ca2+ sensitivity and cross-bridge dissociation that
are independent of dobutamine-induced increase in heart
rate.
Cardiac glycosides and Ca2+-contraction coupling
Digoxin is a clinically used Na+/K+ ATPase inhibitor that
may regulate the formation of actinomyosin cross-bridges
[12], but its effects on Ca2+ affinity for TnCA have yet to be
completely quantified. Our model parameters suggested
that digoxin did not alter myofilament Ca2+ sensitivity or
cross-bridge kinetics before ischemia. The model parame-
ters suggest that digoxin may exert a positive inotropic
effect simply due to the increase in myoplasmic [Ca2+]
(upstream mechanism) in normal myocardium. In con-
trast, after ischemia digoxin was predicted to increase
myofilament Ca2+ sensitivity and cross-bridge kinetics,
and to increase the estimated number of cross-bridges
formed; however, no significant changes were seen in
phase-space diagram size and shape from control after
ischemia. This indicates that though the phase-space rela-
tionship between LVP and [Ca2+] appears unchanged by
digoxin administration from control after IR injury [5],
the model parameters revealed that the mechanism of
Ca2+-contraction coupling had changed significantly from
a primarily upstream mechanism before ischemia to a
more central and downstream mechanism after ischemia.
Another cardiac glycoside, oaubain, was shown to have
similar effects on the ventricular myocardium of patients
with heart failure as those we observed with digoxin after
IR injury [13].
Ca2+ sensitizers and Ca2+-contraction coupling
A newer class of positive inotropic agents is the so-called
myofilament Ca2+ sensitizers. These drugs enhance con-
tractility by either acting directly on TnCA to enhance the
Ca2+ binding mechanism (central mechanism), or by pro-
ducing an increase in cross-bridge binding (downstream
mechanism) in the absence of an increase in the total
amount of activator Ca2+ [36]. Levosimendan is a myofil-
ament Ca2+ sensitizer when administered at low concen-
trations, but also acts as a phosphodiesterase (PDE)
inhibitor at higher concentrations [37]. Levosimendan is
believed to bind to TnCA in the presence of Ca2+ and to
stabilize the Ca2+-TnCA complex without actually increas-
ing Ca2+ binding affinity with TnCA [15]. In guinea pig
papillary muscles, paced at room temperature, levosi-
mendan enhanced cross-bridge attachments while decel-
erating their detachments [16,17].
Our results from the estimated model parameters showed
that levosimendan had little effect on myofilament Ca2+
sensitivity or cross-bridge kinetics before ischemia. This
lack of effect may be dose related or due to differences in
experimental methods, specifically paced muscle strips vs.
freely beating intact hearts. Our data suggests that levosi-
mendan increases contractile function by increasing avail-
able [Ca2+] when administered before ischemia [5].
Levosimendan also increased heart rate before ischemia,
but the model predicted unchanged values of Kd, and Kd'.
This may result from a proportional increase in the
number of cross-bridges and/or a prolonged attachment
of cross-bridges. In contrast to its effects before ischemia,
the model predicted that after ischemia levosimendan
increases Ca2+ affinity for TnCA and the basal rate con-
stant of cross-bridge association to function more as a
classic Ca2+ sensitizing agent. But simultaneous increases
in the predicted rate constants of dissociation of Ca2+ from
TnCA and cross-bridge dissociation may be related to PDE
inhibition by this concentration of levosimendan after
ischemia.
Potential limitations
This model of Ca2+-contraction coupling relies on Ca2+
transients obtained via an optic probe with a transmural
measurement field and surface area of approximately 3
mm2. The model parameters are optimized to best fit iso-
volumic LVP, a more global measurement. One of the
implicit assumptions of this model is that the local Ca2+
transient is a true representation of Ca2+ kinetics in the
entire ventricular wall regardless of orientation of the
individual myocytes which are known to be markedly dif-
ferent from endocardium to epicardium [38].
Because these hearts were unpaced, changes in heart rate
with inotropic interventions likely confound some of the
conclusions drawn from our model parameters. However,
only by allowing hearts to beat at their inherent rhythm
can we fully understand the physiologic impact of these
drugs on the intact heart. Controlling the heart rate would
lead to changes in the peak values and kinetics of the
measured Ca2+ transients and thus result in LVP values
that are non-physiologic.
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Another potential limitation of this model is the presence
of lumped parameters as a result of oversimplification of
the mechanism of protein-protein interactions. For exam-
ple, cross-bridge dissociation is modeled as one rate con-
stant (Kd or Kd') and so reactions associated with myosin
ATPase activity are not distinguished. As a result the
model parameters represent relative, and not absolute,
rates of myofilament Ca2+ sensitivity and cross-bridge
kinetics.
Conclusion
In summary, we used a 4-state computational model to
predict the relationship between [Ca2+] and LVP during
the cardiac cycle in the guinea pig isolated heart when
exposed to positive inotropic drugs before and after global
ischemia. The changes in estimated values of rate con-
stants before and after ischemia appeared to coincide with
known changes in cross-bridge formation and myofila-
ment Ca2+ sensitivity and helped to resolve controversial
findings regarding drug effects on central and downstream
mechanisms after ischemia. The model also predicted dif-
ferential changes in contractile protein interactions based
on post-synaptic receptor adrenergic or dopaminergic
activation. Moreover, the model parameters predicted
that digoxin and levosimendan have little effect on central
and downstream mechanisms prior to ischemia but that
both significantly improve myofilament Ca2+ sensitivity
and cross-bridge cycling after ischemia. These mathemati-
cal characterizations should facilitate future studies that
aim to analyze the effects of preconditioning or heart fail-
ure on contractile kinetics. The phase-space relationship
between experimentally measured [Ca2+] and LVP is use-
ful as a framework to model the theoretical effects of these
interventions on Ca2+-contraction coupling.
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